Is there an increased risk of hip fracture in patients on long-term PPI therapy?: Commentary

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 4, Issue 8, 2007, Pages 420-421

  Talley, Nicholas J ^a   Jung, Hye Kyung ^a   Jiang, Xuan ^a   Locke, G Richard ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; OMEPRAZOLE; PROTON PUMP INHIBITOR; VITAMIN D;

BONE DENSITY; DATA ANALYSIS; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; GASTROESOPHAGEAL REFLUX; GENERAL PRACTITIONER; HEPATITIS; HIP FRACTURE; HUMAN; INCIDENCE; INFORMATION PROCESSING; INTERSTITIAL NEPHRITIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; SIDE EFFECT; STOMACH POLYP; TREATMENT DURATION; UNITED KINGDOM;

EID: 34547702194     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep0870     Document Type: Short Survey

References (5)

1. Thorens J et al. (1996) Bacterial overgrowth during treatment with orneprazole compared with cimetidine: A prospective randomised double blind study. Gut 39: 54-59
2. Raghunath AS et al. (2005) Review article: The long-term use of proton-pump inhibitors. Aliment Pharmacol Ther 22: 55-63
3. Boutet RM et al. (1999) Survey on repeat prescribing for acid suppression drugs in primary care in Cornwall and the Isles of Scilly. Aliment Pharmacol Ther 13: 813-817
4. Jalving M et al. (2006) Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther 24: 1341-1348
5. Bateman DN et al. (2003) Mortality study of 18,000 patients treated with omeprazole. Gut 52: 942-946